Van beleggers
voor beleggers
desktop iconMarkt Monitor

Inloggen

  • Geen account? Registreren

Wachtwoord vergeten?

LAVA Therapeutics

9 Posts
| Omlaag ↓
  1. fly like an eagle 19 mei 2021 11:38
    LAVA is jong bedrijf in Utrecht dat met een scientific co-founder ex Genmab recent op de Nasdaq staat genoteerd en mooie kanzen biedt. Ik heb eerder Argenix en Merus op dit forum onder de aandacht gebracht. ArgenX is gaan vliegen en Merus gaat beslist volgen. LAVA is een nieuwe parel die heel snel gaat. Onder recente aanbeveling

    finance.yahoo.com/news/buy-2-stocks-j...
  2. fly like an eagle 19 mei 2021 12:12
    LAVA Therapeutics (LVTX)

    We’ll start with a Netherlands-based biotech firm. LAVA Therapeutics has a focus on cancer treatments, and is working to develop what it calls gamma-delta bispecific T cell engagers. These compounds are intended to activate the innate and adaptive immune systems, using the body’s own response to fight tumors.

    LAVA’s pipeline includes four proprietary compounds, and a fifth that is being investigated in combination with Janssen. All five drug candidates are in preclinical trials. The leading candidate, LAVA-051, is scheduled to begin a Phase 1/2a clinical trial in the first half of this year, while a second candidate, LAVA-1207, will begin a Phase 1/2a trial during 2H21. These drug candidates are being developed as treatments for multiple myeloma and prostate cancer, respectively.

    LVTX shares entered the public markets on March 25, in an IPO that raised $100.5 million. The shares started trading at $15, and saw 6.7 million shares hit the market.

    Among the bulls is JPM analyst Jessica Fye, who likes the fundamental of this newly public stock. Fye rates LVTX an Overweight (i.e. Buy), and her $22 price target implies a robust upside potential of ~86% for the year ahead. (To watch Fye’s track record, click here)

    "Our Overweight rating is based on our positive view of the company’s proprietary platform, gamma-delta bsTCE, which redirects a specific group of T cells called gamma-delta T cells towards tumor cells. We see LAVA’s off-the-shelf bsTCEs, which can conditionally activate gamma-delta T cells in a tumor/antigen directed manner, as differentiated, potentially leading to a safer therapy and more durable benefit. To the extent that initial data for lead asset LAVA-051 begins to derisk the platform, we see upside for shares as soon as early 2022," Fye noted.

    In its short time on the public market, LAVA’s unique approach to cancer treatment has attracted notice from three Wall Street biotech analysts – and all three agree that this is a stock to buy, making the Strong Buy consensus rating unanimous. The shares are trading for $11.80, and their $23.67 average price target is even more bullish Fye allows, suggesting an upside of ~100% in the next 12 months. (See LVTX stock analysis on TipRanks)
  3. fly like an eagle 21 mei 2021 12:39
    LAVA Therapeutics Provides Business Update and Reports First Quarter Financial Results

    May 20, 2021 06:30 ET | Source: LAVA Therapeutics BV

    ...

    IPO bolsters balance sheet to $160 million in cash and cash equivalents; expected to fund operations at least into the second half of 2023

    Clinical development plans on schedule in both hematological and solid tumor programs

    Leadership strengthened through key management and board appointments

    UTRECHT, The Netherlands and PHILADELPHIA, May 20, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a biotechnology company focused on applying its expertise in gamma-delta bispecific T cell engagers (bsTCEs) to transform cancer therapy, today reported its business update and first quarter 2021 financial results.

    “We continue to make important strides across all aspects of our business as we transition to a clinical stage organization,” said Stephen Hurly, chief executive officer of LAVA Therapeutics. “With the recent additions to our leadership team and board and the proceeds from our IPO, we are well-positioned to advance our pipeline as we work toward our mission of transforming cancer therapy for patients.”

    Recent Business and Pipeline Highlights

    Phase 1/2a Clinical Trial of LAVA-051 for Multiple Hematological Malignancies on Track: LAVA is on track to initiate its open-label, multi-center, Phase 1/2a clinical trial of LAVA-051 for the treatment of relapsed and/or refractory chronic lymphocytic leukemia (CLL), multiple myeloma (MM) and acute myeloid leukemia (AML) in the first half of 2021. The trial is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary antitumor activity of LAVA-051.

    Preclinical Data Supporting Anti-Tumor Activity of LAVA-051 Presented at AACR Virtual 2021 Annual Meeting: In April 2021, LAVA presented preclinical data on LAVA-051 at the virtual American Association for Cancer Research (AACR) Annual Meeting. The data demonstrated that LAVA-051 exerted substantial antitumor activity against patient derived CLL, MM and AML cells that express CD1d. In addition, improved survival was observed in in vivo AML and MM mouse xenograft models treated with LAVA-051.

    Successful Initial Public Offering Completed: In March 2021, LAVA priced its initial public offering (IPO) at $15.00 per share. In connection with the offering, the Company issued 7,125,712 common shares resulting in gross proceeds, before deducting underwriting discounts and commissions and offering expenses payable by LAVA, of approximately $107 million.
  4. Tauromaquia 2 juni 2021 15:28
    Je haalt ArgenX en Merus aan: ik begrijp dat we interesse hebben in dezelfde bedrijven ;-)

    Wat betreft LAVA therapeutics: Als deze eerste klinische studie licht positieve resultaten geeft, dan is dat gelijk een validatie van het gehele platform dat het bedrijf in ontwikkeling heeft. Op het moment kan ik moeilijk inschatten of het bedrijf juist gewaardeerd is (alle programma's zijn nog erg vroeg!).Ik blijf het met interesse volgen!
  5. fly like an eagle 7 juni 2021 11:19
    Klopt en het is afwachten op het hen lukt het platform te valideren maar Paul Parren ex-Genmab is slimme gast net als Hans de Haard van Argenx en Ton Logtenberg van Merus. ArgenX heeft het meer dan geweldig gedaan en ik ben overtuigd dat Merus met zijn bispecifieke antibodies ook zal slagen.
9 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord

Direct naar Forum

Indices

AEX 754,31 -0,50%
EUR/USD 1,1869 0,00%
Germany30^ 15.549,40 -0,58%
Gold spot 1.814,01 0,00%
LONDEN-FTSE 100 7.032,30 -0,65%
NY-Nasdaq Composite 14.672,68 -0,71%

Stijgers

CM.COM
+2,82%
Brunel
+2,76%
CTP
+1,80%
WDP
+1,74%
Avantium
+1,70%

Dalers

INPOST
-5,82%
Air Fr...
-4,58%
Fugro
-4,23%
UNIBAI...
-3,78%
AMG
-2,95%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links